The New England journal of medicine, 2020-07, Vol.383 (5), p.498-500
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
- Ist Teil von
- The New England journal of medicine, 2020-07, Vol.383 (5), p.498-500
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMc2005943Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7456330
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents - therapeutic use, Chromosome 17, Chronic lymphocytic leukemia, Disease Progression, Female, Follow-Up Studies, Humans, Kinases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell - genetics, Leukemia, Lymphocytic, Chronic, B-Cell - mortality, Lymphatic leukemia, Male, Middle Aged, Mutation, p53 Protein, Protein Kinase Inhibitors - therapeutic use, Pyrazoles - therapeutic use, Pyrimidines - therapeutic use, Survival Analysis, Tumor Suppressor Protein p53 - genetics